News + Font Resize -

Phase III EMILIA study shows Roche's trastuzumab emtansine improves survival of people with HER2-positive metastatic breast cancer
Basel | Tuesday, August 28, 2012, 10:00 Hrs  [IST]

Roche, a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics,  has updated results from the phase III EMILIA study, which showed that trastuzumab emtansine (T-DM1) significantly extended the lives (improved overall survival) of people with HER2-positive metastatic breast cancer (mBC) compared to the combination of lapatinib and Xeloda (capecitabine).

The EMILIA study, in people with HER2-positive mBC who had previously received Herceptin (trastuzumab) and taxane chemotherapy, has now met both co-primary efficacy endpoints of significant improvements in overall survival and progression-free survival (PFS). These data will be presented at an upcoming medical meeting.

Genentech has submitted a Biologics Licence Application (BLA) for trastuzumab emtansine to the US Food and Drug Administration (FDA) and Roche will shortly be submitting a Marketing Authorisation Application to the European Medicines Agency (EMA).

“We are extremely pleased to announce that people treated with trastuzumab emtansine survived significantly longer than those who received a standard option for this aggressive advanced breast cancer,” said Hal Barron, MD, chief medical officer and Head, Global Product Development. “We believe that antibody-drug conjugates have the potential to change the future treatment of cancer, and we look forward to working with regulatory authorities in the hope of bringing another potential treatment option to people with HER2-positive metastatic breast cancer.”

Based on these updated overall survival results, people in the lapatinib and Xeloda arm of EMILIA will be offered the option to receive trastuzumab emtansine.

Trastuzumab emtansine is an antibody-drug conjugate (ADC) being studied in HER2-positive cancers. It is comprised of the antibody trastuzumab and the chemotherapy DM1 attached together using a stable linker. Trastuzumab emtansine is designed to target and inhibit HER2 signalling and deliver the chemotherapy DM1 directly inside HER2-positive cancer cells. Roche has been researching the HER2 pathway for three decades. The development of HER2-targeted therapies represents one of the first successful examples of personalised healthcare.

EMILIA (TDM4370g/BO21977) is an international, phase III, randomised, open-label study comparing trastuzumab emtansine alone to lapatinib in combination with Xeloda in 991 people with HER2-positive locally advanced or metastatic breast cancer who had previously been treated with Herceptin and a taxane-based chemotherapy.

The co-primary efficacy endpoints of the study are PFS (as assessed by an independent review committee) and overall survival. Other study endpoints include one-year and two-year survival rates, safety profile, PFS as assessed by investigator, objective response rate, duration of response and quality of life.

This confirmatory analysis of overall survival in the phase III EMILIA study crossed the pre-specified boundary that showed trastuzumab emtansine significantly extended the lives of people with HER2-positive mBC compared to the combination of lapatinib and Xeloda.

Trastuzumab emtansine is an antibody-drug conjugate (ADC) being studied in HER2-positive cancers. It is comprised of the antibody trastuzumab and the chemotherapy DM1 attached together using a stable linker. Trastuzumab emtansine has the mechanisms of action of both trastuzumab and DM1. Trastuzumab emtansine is designed to target and inhibit HER2 signalling and deliver the chemotherapy DM1 directly inside HER2-positive cancer cells. Trastuzumab emtansine binds to the HER2-positive cancer cells, and is thought to block out-of-control signals that make the cancer grow while also calling on the body's immune system to attack the cancer cells. Once trastuzumab emtansine is absorbed into those cancer cells, it is designed to destroy them by releasing the DM1.

Genentech, a member of the Roche Group, licenses technology for trastuzumab emtansine under an agreement with ImmunoGen, Inc.

Post Your Comment

 

Enquiry Form